4.7 Article

Potentialities of nanomaterials for the management and treatment of metabolic syndrome: A new insight

期刊

MATERIALS TODAY ADVANCES
卷 13, 期 -, 页码 -

出版社

ELSEVIER
DOI: 10.1016/j.mtadv.2021.100198

关键词

Nanomaterials; Metabolic syndrome (MS); Nanotechnology; Phytochemicals

资金

  1. BHU (IoE seed grant project)
  2. DST-INSPIRE faculty Fellowship, BHU (IoE grant)
  3. UGC New Delhi
  4. IGNTU, Amarkantak, India

向作者/读者索取更多资源

Metabolic syndrome is a cluster of abnormalities that significantly increase the risk of developing type 2 diabetes and cardiovascular diseases. Despite limitations in current therapies, nanotechnology is emerging as a promising tool for managing metabolic disorders, offering targeted drug delivery and early disease detection benefits.
Metabolic syndrome is a collection of abnormalities including insulin resistance, hypertension, dyslipidemia, type 2 diabetes, obesity, inflammation, non-alcoholic fatty liver disease, etc. The metabolic syndrome results in a dramatic five-fold elevation in the risk of developing type-2 diabetes and a two-fold heightened risk of developing cardiovascular diseases. It is fast becoming a major global health challenge, cause of mortality and morbidity. Regardless of advances in understanding the mechanisms involved in the pathogenesis of metabolic syndrome, available therapies are still not effective. Nanotechnology is marked as an upcoming tool with a wide range of applications in biomedicine, especially for the management of metabolic syndrome and its associated disorders such as diabetes, obesity, etc. because the nanotechnology utilizes nanoscaled drugs and therapeutics that can reach specific target sites, which helps in improving drug delivery systems, early disease detection and diagnosis using nano-imaging techniques. Therefore, nanotechnology increases bioavailability, permeability, compatibility, the effectiveness of treatment and reduced adverse effects. In this review, we will describe the role of nanomaterial-based therapeutics in managing metabolic disorders such as non-alcoholic fatty liver disease, obesity, insulin resistance, glucose intolerance which all increase the risk of developing cardiovascular diseases and diabetes. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据